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Introduction: Ovarian cancer (OvCa) is the most lethal gynecologic malignancy in the
United States because of chemoresistant recurrent disease. Our objective was to inves-
tigate the efﬁcacy of inhibiting the Notch pathway with a g-secretase inhibitor (GSI) in an
OvCa patient-derived xenograft model as a single agent therapy and in combination with
standard chemotherapy.
Methods: Immunocompromised mice bearing xenografts derived from clinically platinum-
sensitive human ovarian serous carcinomas were treated with vehicle, GSI (MRK-003)
alone, paclitaxel and carboplatin (P/C) alone, or the combination of GSI and P/C. Mice bear-
ingplatinum-resistantxenograftsweregivenGSIwithorwithoutpaclitaxel.Genetranscript
levels of the Notch pathway target Hes1 were analyzed using RT-PCR. Notch1 and Notch3
protein levels were evaluated.TheWilcoxon rank-sum test was used to assess signiﬁcance
between the different treatment groups.
Results: Expression of Notch1 and 3 was variable. GSI alone decreased tumor growth
in two of three platinum-sensitive ovarian tumors (p <0.05), as well as in one of three
platinum-sensitive tumors (p D0.04). The combination of GSI and paclitaxel was signiﬁ-
cantly more effective than GSI alone and paclitaxel alone in all platinum-resistant ovarian
tumors (all p <0.05).The addition of GSI did not alter the effect of P/C in platinum-sensitive
tumors. Interestingly, although the response of each tumor to chronic GSI exposure did not
correlate with its endogenous level of Notch expression, GSI did negatively affect Notch
signaling in an acute setting.
Conclusion: Inhibiting the Notch signaling cascade with a GSI reduces primary human
xenograft growth in vivo. GSI synergized with conventional cytotoxic chemotherapy only
in the platinum-resistant OvCa models with single agent paclitaxel. These ﬁndings sug-
gest inhibition of the Notch pathway in concert with taxane therapy may hold promise for
treatment of platinum-resistant OvCa.
Keywords: ovarian cancer, Notch, g-secretase inhibitor, chemoresistance, patient-derived xenograft
INTRODUCTION
Ovarian cancer(OvCa)representsthesecondmostcommon,and
most lethal gynecologic malignancy in the United States. By the
end of 2013,it is estimated that over 22,000 women will have been
diagnosed with OvCa, and more than 15,000 patients will have
succumbed to the disease (1). The high death rate is due in part to
the fact that the majority of patients present with advanced stage
disease possibly due to a lack of screening strategies that effec-
tively detect the cancer in early stages. The most common subtype
is high-grade serous carcinoma (70%), followed by endometrioid
and clear cell variants (2). Despite the histologic variation, the
current treatment regimen includes cytoreductive surgery as well
as six cycles of taxane and platinum-based chemotherapy deliv-
ered IV or IP (3, 4). While 70–80% of patients respond to this
ﬁrst-linechemotherapy,recurrencesoccurfrequentlyandasignif-
icantmajorityof thosepatientsdevelopchemoresistantdisease(5,
6). The overall prognosis of patients diagnosed with OvCa there-
fore remains poor, with a 5-year survival rate of approximately
50% (4). Insights into key molecular pathways that are overex-
pressedinOvCaandcontributetotumorprogression,recurrence,
andchemoresistancemayleadtonoveltherapiesthatcanimprove
the treatment strategies for these women.
The Notch signaling cascade has been implicated in numer-
ous malignancies (7–11) and is one of the most altered pathways
in serous OvCa (2). Notch signaling is involved in the regulation
of proliferation,differentiation,cellfate,andsurvivalandplaysan
importantroleinembryonicdevelopmentaswellasinself-renewal
of adult stem/progenitor cells (12–14). Activation of the Notch
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signaling cascade occurs through binding of one of four Notch
receptors (Notch1–4) with one of its ligands (Jagged and Delta-
like) on a neighboring cell. Sequential proteolytic cleavage of the
Notchreceptorbyadisintegrinandmetalloprotease(ADAM)and
g-secretase leads to the release of the Notch intracellular domain
(NICD). This active fragment subsequently translocates to the
nucleus, where it activates transcription of target genes including
members of the HES and HEY families (12, 15).
Recent studies have demonstrated expression of the Notch
pathway in many malignancies including breast, intestinal, pan-
creatic,brain,andOvCa(10,16–21).Genomicanalysesof ovarian
carcinomas as part of The Cancer Genome Atlas (TCGA) Project
showed alteration of Notch signaling in 22% of analyzed tumors
(2). In addition, Notch1 and Notch3 RNA transcript and pro-
tein are highly expressed in ovarian carcinomas (22–27) and ele-
vated expression correlates with resistance to chemotherapy and
decreased survival (28–30). Investigators have hypothesized that
Notchsignalingmaypromotetheactivityofatumor-initiatingcell
population that can sustain the growth of ovarian tumors despite
cytotoxic therapies that halt the progression of actively proliferat-
ing cancer cells (31–33). While this hypothesis is controversial, it
would provide rationale for combining Notch pathway inhibition
with conventional cytotoxic therapy.
Targeting of the Notch pathway is currently being investigated
inavarietyof cancers,withg-secretaseinhibitors(GSIs)beingthe
most widely used Notch inhibitors (34, 35). Few phase I and II
clinical trials have reported GSI anti-tumor activity though these
studies have included only a few women with OvCa. Previous
pre-clinical studies have shown that inhibition of Notch signal-
ing blocks the growth of both OvCa cell lines in vitro and cell
line-derived xenografts in vivo (36–38). In addition to inhibition
of cell proliferation and induction of cell death, treatment with
GSI is associated with an increased sensitivity of OvCa cell lines
to platinum therapy (39) supporting the concept that treatment
with Notch antagonists may be relevant in a recurrent disease
setting (28).
Inthecurrentstudy,weanalyzedthecontributionof theNotch
pathway to the pathobiology of serous OvCa. We assessed the
expression of speciﬁc members of the Notch family and tested the
anti-tumor activity of the GSI MRK-003 against patient-derived
xenografts(PDXs)generatedfromserouscarcinomasof theovary
or peritoneum. The pre-clinical efﬁcacy of MRK-003 has been
determined in several human cancers (8, 9, 34, 40–43), and we
wantedtoassesstheeffectivenessofthisGSIasasingleagentandin
combinationwithstandardcytotoxicchemotherapyinacohortof
clinically platinum-sensitive and resistant ovarian tumors. Treat-
ment of mice harboring the ovarian tumor xenografts with MRK-
003 resulted in reduced tumor growth in a subset of experiments.
CombinationcytotoxicchemotherapyandGSIdemonstratedsyn-
ergisticactivityonlyinthoseplatinum-resistanttumorssuggesting
Notch pathway inhibition may be more effective in the recurrent
and refractory setting.
MATERIALS AND METHODS
GENERATION AND PROPAGATION OF OVARIAN CANCER XENOGRAFTS
Our PDX model utilizing primary human ovarian tumors has
been described previously (44). Brieﬂy, excess serous OvCa tissue
or ascites was obtained at the time of surgery from patients
who had given informed consent to participate in an Institu-
tional Review Board approved tissue collection protocol. Follow-
ing enzymatic processing, tumor-derived single-cell suspensions
weredepletedof hematopoieticandendothelialcells,resuspended
in PBS, mixed with Matrigel (1:1), and injected subcutaneously
(s.c.) in female NOD/SCID mice. The range of cells injected
was 7.5105 to 1.5106 in each animal. Tumor formation in
the injected animals was regularly monitored, and tumors were
harvested from euthanized animals when they reached a diame-
ter of 1–2cm. The harvested xenografts were then enzymatically
processed, depleted of H-2Kd positive mouse cells, and injected
s.c. into NOD/SCID mice as described above. Using this trans-
plantation system,cohorts of 15–40 mice injected with OvCa cells
derived from a single patient were generated and subsequently
used to perform treatment experiments.
IMMUNOHISTOCHEMICAL ANALYSIS
Notch1 and Notch3 protein expression in formaldehyde ﬁxed and
parafﬁn embedded sections of primary and xenograft ovarian
tumors were analyzed by immunohistochemistry (IHC) using a
mouse monoclonal anti-Notch1 antibody (Novus Biologicals) or
a rabbit polyclonal anti-Notch3 antibody (Abgent). Non-speciﬁc
binding of antibody was blocked by either the Vector Labora-
tories M.O.M. kit (in the case of Notch1) or 5% normal goat
seruminPBSwith0.1%TritonX(Notch3)followedbyincubation
with the relevant primary antibody and the appropriate biotiny-
lated secondary antibody. Subsequent treatment with Vectas-
tain ABC reagents (Vector Laboratories), visualization with 3,30-
diaminobenzidine chromogen (DAB, Dako), and counterstaining
with hematoxylin were performed.
IMMUNOBLOTTING
Wholecelllysateswerepreparedfromfrozenxenograftsamplesor
cell lines using Mammalian Protein Extraction Reagent (Thermo
Scientiﬁc) lysis buffer supplemented with inhibitors of endoge-
nous protease,kinase,and phosphatase activity (all obtained from
Sigma-Aldrich). Twenty micrograms of protein from each sample
were separated on 7.5 or 10% polyacrylamide gels and trans-
ferred to a PVDF membrane. Following transfer, membranes
were blocked with 5% milk in 1 TBS, 0.1% Tween-20 (TBST)
and incubated in diluted (1:1000) primary antibody overnight,
according to the manufacturer’s recommendations. Primary anti-
bodies used were a rabbit monoclonal anti-Notch1 antibody,
a rabbit monoclonal anti-cleaved Notch1 (Val1744) antibody,
and a rabbit monoclonal anti-Notch3 antibody (Cell Signaling).
Membranes were then incubated with a horseradish peroxidase
(HRP) conjugated goat anti-rabbit secondary antibody (Santa
Cruz Biotechnology) and developed using a chemiluminescent
detection reagent obtained from GE Healthcare Life Sciences.
Equivalent protein loading was veriﬁed by stripping the blots and
re-probing with a mouse anti-Pan-Actin antibody (NeoMarkers).
CELL CULTURE AND IN VITRO TREATMENT WITH MRK-003
The OVCAR3 and SKOV3 human OvCa cell lines were purchased
fromATCC.ForMRK-003doseresponseexperiments,equalnum-
bers of OVCAR3 or SKOV3 cells were plated and serum-starved
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overnightingrowthmediumcontaining1%FBS.Cellswereincu-
bated in triplicate (OVCAR3) or quadruplicate (SKOV3) with
either 0, 1, 5, or 10mM MRK-003. After 48h, cells were harvested
and quantiﬁed. Subsequently, OVCAR3 and SKOV3 cells were
treated with either the relevant MRK-003 IC50 or vehicle control
only. Cells were harvested 6h after administration of MRK-003,
and cell pellets were frozen for immunoblotting and quantitative
PCR analyses.
TREATMENT OF MICE BEARING SEROUS OVARIAN CANCER
XENOGRAFTS
All xenograft tumors were generated from prospectively con-
sented patients, and their clinical response to platinum-based
adjuvant therapy was used to stratify the cohorts of mice bear-
ing serous OvCa xenografts. Tumors collected from patients who
did not develop resurgence of their serous OvCa for longer than
6months were labeled platinum-sensitive. Those tumors derived
frompatientswhodevelopedrecurrence<6monthsweredeemed
to be platinum-resistant. Tumor growth in mice was monitored
regularly, and treatment regimens were started when tumor vol-
umes were 200–400mm3. Mice were then randomly divided into
four cohorts of ﬁve to seven mice each. Mice bearing xenografts
derived from clinically platinum-sensitive OvCa were random-
ized to treatment with either MRK-003 alone (300mg/kg in
0.5% methylcellulose) once weekly by oral gavage, paclitaxel and
carboplatin (P/C) alone, MRK-003 with P/C, or vehicles of all
three drugs. Mice harboring clinically platinum-resistant ovarian
tumors were treated with either MRK-003 alone, paclitaxel alone,
MRK-003 with paclitaxel, or vehicles of MRK-003 and paclitaxel.
Paclitaxel (15mg/kg), carboplatin (50mg/kg), and their appro-
priate vehicles (Cremophor:ethanol and saline, respectively) were
given once weekly by intraperitoneal (i.p.) injection. Tumor vol-
umes were determined every 3–4days, and mice were weighed
weekly. Thelength of experiments wasdetermined bythe individ-
ual tumor growth patterns in the vehicle setting so that all arms of
experiments could be terminated at one time to decrease biologic
variability. At the end of each treatment experiment, mice were
euthanizedandtumorswereharvested.Oneportionofeachtumor
was snap frozen, and a second portion was ﬁxed in formaldehyde
and embedded in parafﬁn.
In order to study the acute effect of MRK-003 treatment
on Notch pathway activation, mice harboring primary OvCa
xenografts were given one dose of MRK-003 or vehicle. Tumors
were harvested 6, 24, or 48h after treatment, and portions were
snap frozen as well as ﬁxed in formaldehyde and embedded in
parafﬁn.
QUANTITATIVE PCR ANALYSIS
RNA was isolated from frozen xenograft tissue or cell pel-
lets using the GenElute mammalian RNA extraction kit
and converted to cDNA (SuperScript VILO, Life Tech-
nologies). Quantitative real-time PCR (qPCR) analysis was
performed with SsoAdvanced SYBR Green Supermix (Bio-
Rad Laboratories) and primers speciﬁc for human Hes1
(forward: 50-ATTCCTCGTCCCCGGTGGCT-30; reverse: 50-
TCCAGCTTGGAATGCCGCGAG-30) and b-actin (forward: 50-
GAGCACAGAGCCTCGCCTTT-30;reverse:50-TCATCATCCATG
GTGAGCTGG-30). For each analyzed sample, relative expression
of Hes1 mRNA normalized to b-actin mRNA was determined as
previously described (45).
STATISTICAL ANALYSIS
Because of the non-normal distribution of tumor volumes, non-
parametric Wilcoxon rank-sum tests were carried out to deter-
mine whether the observed differences in tumor volume between
the groups in each treatment experiment were statistically sig-
niﬁcant. All analyses were done using Stata version 11.1 soft-
ware (StataCorp LP), and a p-value of <0.05 was considered
statistically signiﬁcant.
RESULTS
EXPRESSION OF Notch1 AND Notch3 IN SEROUS OVARIAN CANCER
Notch1andNotch3proteinexpressioninboththeprimaryhuman
papillary serous OvCas that were utilized in the current study
(OV1–OV7; see Table 1) and in xenografts derived from these
patient samples were assessed by IHC (Figures 1A,C). Addition-
ally, Notch1 and Notch3 expression in the same xenografts was
analyzed by immunoblotting (Figures 1B,D).Variable expression
of both Notch1 and Notch3 was found in all primary tumors and
xenografts. IHC revealed that Notch protein levels were consis-
tentbetweeneachprimarytumoranditscorrespondingxenograft
tumor and largely correlated with the protein level detected by
immunoblotting.
EFFECT OF g-SECRETASE INHIBITION ON OVCAR3 AND SKOV3 CELL
PROLIFERATION AND CLEAVED Notch1 AND Hes1 LEVELS
OVCAR3 and SKOV3 cells were treated with 1, 5, and 10mM
MRK-003. After an incubation period of 48h, a dose-dependent
Table 1 | Clinical characteristics of patients whose tumors were analyzed in this study.
Patient Age at diagnosis Stage Grade Progression free Overall survival Current status
(years) survival (months) (months)
OV1 38.3 IV 3 34.1 57 .9 Alive
OV2 62.7 IIIC 3 23.9 37 .6 Deceased
OV3 60.7 IIIC 3 18.5 24.1 Deceased
OV4 50.8 IIIC 3 22.4 28.9 Alive
OV5 68.4 IIIC 3 7 .9 7 .9 Deceased
OV6 54.8 III ND 7 .1 10.3 Deceased
OV7 90.5 Unstaged ND 4.9 6.5 Deceased
www.frontiersin.org July 2014 | Volume 4 | Article 171 | 3 
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FIGURE 1 |Variable expression of Notch1 and Notch3 in ovarian cancer
specimens. (A,C) Immunohistochemical analyses of Notch1 and Notch3
expression was carried out on xenograft tumors generated from all seven
tumors that were subsequently used for treatment studies (OV1–OV7), as
well as on paired primary tissue samples when available (OV1–OV5).
Representative images of Notch1 (A) and Notch3 (C) immunostaining are
shown. (B,D) Western blotting was performed to analyze expression of
Notch1 (B) and Notch3 (D) in xenografts derived from primary human serous
ovarian cancers (OV1–OV7). Uncleaved, inactivated Notch1 and Notch3 as well
as cleaved activated Notch1 and Notch3 are shown. An anti-Pan-Actin
antibody was used to conﬁrm equivalent loading of samples.The HCC1187
and SKOV3 cell lines were used as a negative control ( Cx) for Notch1 and
Notch3, respectively.The MCF-7 cell line was used as a positive control (CCx)
for both Notch1 and Notch3.
reduction in OVCAR3 and SKOV3 cell counts was found
compared to cells incubated with medium only (see Figure 2A).
Subsequently, OVCAR3 and SKOV3 cells were treated with either
MRK-003 at the relevant IC50 (5mM for OVCAR3, 10mM for
SKOV3) or vehicle control for 6h and then harvested. The impact
of MRK-003 on Notch signaling was assessed by immunoblotting
analysisof g-secretase-cleavedNotch1levelsandqPCRanalysisof
target gene Hes1 expression.We observed both a strong reduction
in cleaved Notch1 protein levels as well as a marked decrease in
Hes1 gene expression relative to the vehicle treated control in both
cell lines following treatment with MRK-003 (see Figures 2B,C).
IMPACT OF MRK-003 IN VIVO TREATMENT ON Hes1 EXPRESSION
Our in vitro data suggest that MRK-003 speciﬁcally targets the
Notch pathway in OvCa cell lines. To extend these ﬁndings, we
assessed the effect of MRK-003 on Notch signaling in PDXs.
OvCa xenografts were harvested from mice 6, 24, or 48h after
administration of a single dose of MRK-003 or vehicle con-
trol and expression of the Notch target gene Hes1 was ana-
lyzed by qPCR. In all analyzed xenografts, a 30–70% decrease
in Hes1 mRNA levels, relative to levels in vehicle treated con-
trols, was observed after exposure to MRK-003. Figure 3 is
a representative example of these analyses and illustrates the
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FIGURE 2 |The g-secretase inhibitor MRK-003 inhibits OVCAR3 and
SKOV3 cell proliferation and decreases NICD1 and Hes1. (A) In vitro
treatment of OVCAR3 and SKOV3 cells with MRK-003 leads to a
dose-dependent reduction of cell proliferation. Cells were incubated with
increasing concentrations (0–10mM) of MRK-003 for 48h in medium
containing 1% FBS. OVCAR3 cells were treated in triplicate, and SKOV3
cells were treated in quadruplicate. Average relative changes in cell
numbers are shown, and error bars represent the standard error of the
mean. (B) Western blotting analysis of OVCAR3 and SKOV3 cells incubated
with 5mM (OVCAR3) or 10mM (SKOV3) MRK-003 for 6h reveals a marked
decrease in expression of cleaved Notch1 (Val1744). An anti-Pan-Actin
antibody was used to conﬁrm equivalent loading of samples.
ControlDcells incubated with medium only. (C) qPCR analysis of Hes1
gene expression in MRK-003 treated OVCAR3 and SKOV3 cells, harvested
6h post treatment, showed signiﬁcantly decreased Hes1 transcript levels
compared with cells incubated with medium only. Relative changes in
Hes1 mRNA expression are shown, normalized to expression of
housekeeping gene b-actin.
relative transcript levels of Hes1 in OV5 xenografts collected
6h after treatment with MRK-003 or vehicle. OV5 was selected
as a representative example as this was a platinum-resistant
tumor that demonstrated a potent synergy with paclitaxel in our
in vivo experiments.
ASSESSMENT OF THE IMPACT OF MRK-003 AS A SINGLE AGENT OR IN
COMBINATION WITH CYTOTOXIC CHEMOTHERAPEUTICS ON OVARIAN
CANCER XENOGRAFTS
The clinical characteristics of the seven patients whose tumors
were used to generate primary xenografts are summarized in
www.frontiersin.org July 2014 | Volume 4 | Article 171 | 5 
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FIGURE 3 |Treatment with MRK-003 decreases Hes1 expression
in vivo. qPCR analysis of Hes1 gene expression was performed using
xenograft samples collected 6, 24, and 48h after treatment with MRK-003
or vehicle. Hes1 expression in OV5 xenografts collected 6h after
administration of MRK-003 (nD2) or vehicle (nD2) is shown. Average
relative changes in Hes1 mRNA expression were determined following
normalization to b-actin expression. Error bars represent the standard error
of the mean.
Table 1. Brieﬂy, all samples were obtained from women with
primarily advanced stage disease, three of whom manifested
platinum-sensitive disease and markedly improved survival com-
pared to the platinum-resistant patients. In three independent
experiments,miceharboringxenograftsderivedfromaplatinum-
sensitivetumorwererandomizedtoreceiveeitherMRK-003alone,
P/C alone, the combination of MRK-003 and P/C, or vehicle
alone. We observed a signiﬁcant reduction in OV3 (p D0.02) and
OV4 (p <0.01) PDX growth following administration of MRK-
003 alone, compared with vehicle treated control tumors (see
Figure4).TreatmentwithP/Calonesigniﬁcantlydecreasedtumor
volumes of all three analyzed platinum-sensitive PDXs, and com-
bination therapy with MRK-003 and P/C was not more effective
than treatment with P/C alone (see Figure 4). In Figure 4A, the
combined P/C and MRK-003 arm was truncated early so that
tumor could be harvested for post treatment investigation. No
signs of toxicity were observed in mice receiving MRK-003 and
animal weights remained stable during the course of treatment
(data not shown).
The three primary human platinum-resistant serous ovarian
tumors were also established as PDXs in immunocompromised
mice. In three separate experiments, mice harboring the tumors
were subjected to therapy with either MRK-003 alone, pacli-
taxel alone, MRK-003 in combination with paclitaxel, or vehicle
alone. In all analyzed tumors, enhanced anti-tumor activity was
found in mice treated with the combination of MRK-003 and
paclitaxel, compared with paclitaxel alone and MRK-003 alone
(p <0.03, see Figure 5). Administration of paclitaxel as a single
agent led to a signiﬁcant decrease of xenograft growth in only
one of three tumors (OV7, p <0.01, see Figure 5C). In addition,
MRK-003monotherapyledtosigniﬁcanttumorgrowthreduction
of OV5 xenografts, compared with vehicle treatment (p D0.04,
see Figure 5A). Again, no signiﬁcant weight loss or other signs of
toxicity were observed in mice treated with MRK-003 (data not
shown).
DISCUSSION
Inthecurrentstudy,weconﬁrmthatmembersoftheNotchsignal-
ing pathway are expressed in serous OvCa,and GSI-mediated tar-
getingofthispathwayleadstoanti-proliferativeeffectsinvitro and
anti-tumoractivityinvivo.WhilesingleagentGSIwastumorstatic
in half of the analyzed PDXs,combination therapy with cytotoxic
chemotherapyledtosigniﬁcantsynergisticanti-tumoreffectsonly
in those xenografts originally derived from platinum-resistant
OvCa patients. Collectively, these pilot data support the role of
NotchsignalinginOvCagrowthparticularlyinthechemoresistant
setting.
Various studies have detected Notch1 and Notch3 expression
in ovarian tumors by IHC, real-time polymerase chain reaction,
and/or immunoblotting. The results for Notch1 expression via
detection by IHC have been variable and difﬁcult to interpret.
In one study of relative Notch1 expression in benign ovarian tis-
sue and a spectrum of low- to high-grade ovarian carcinomas,
Notch1 was rarely detected in benign tissue and its expression
level correlated with increasing grade and clinical stage of dis-
ease (23). Interestingly, Notch1 was primarily conﬁned to the cell
membraneandthecytoplasm.Thedirectfunctionalorclinicalsig-
niﬁcance of increased cytoplasmic expression in OvCa is unclear
given that cleaved Notch1 migrates to the nucleus and is consid-
ered the active form. In similar immunohistochemical analyses,
no nuclear Notch1 expression was detected suggesting little to no
role for Notch1 in OvCa (46). In contrast,Notch1 nuclear expres-
sion was evident in our cohort of samples but was highly variable
among and within samples. Despite the variation between sam-
ples, however, the intensity of nuclear Notch1 expression in each
primary tumor and its correlate xenografts was stable reinforc-
ing that Notch1 expression remains consistent across subsequent
xenograft generations. These data suggest that protein expression
of Notch1 or 3 does not correlate with response to GSI suggesting
many other molecular inputs must be involved with modulating
response in the platinum-resistant setting.
While Notch1 IHC studies have generated conﬂicting results,
immunoblotting analyses that have largely focused on Notch1
NICD expression in primary samples and established human
OvCa cell lines are much less controversial. Rose et al. (22) found
abundant levels of cleaved Notch1 in the OVCAR3, SKOV3, and
CaOV3 cell lines as well as in approximately 75% of the pri-
mary OvCa samples analyzed. Consistent with published work
(22, 36), we similarly detected cleaved Notch1 in OvCa cell lines
and primary ovarian tumor samples by immunoblotting. Thus,
in contrast to the collective IHC results, the data to date suggest
that cleaved Notch1 is present in some samples thereby providing
indirect evidence that Notch1 signaling is active in OvCa.
This hypothesis is further bolstered by functional studies that
suggest Notch1 promotes OvCa cell proliferation. In one investi-
gation, stable transfection of A2780 OvCa cells with the Notch1
NICD increased both cell proliferation and the rate of colony
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FIGURE 4 | MRK-003 treatment in vivo inhibits tumor growth in the
majority of analyzed platinum-sensitive ovarian cancers.Three
independent cohorts of mice bearing xenografts derived from clinically
platinum-sensitive serous ovarian cancer were treated with vehicle, MRK-003
alone, paclitaxel/carboplatin (P/C) alone or P/CCMRK-003. A signiﬁcant
anti-tumor effect of treatment with MRK-003 alone was observed in OV3
(B) and OV4 (C) xenografts (p <0.05). P/C alone and P/CCMRK-003 were
equally effective in signiﬁcantly reducing tumor growth of OV2 (A), OV3, and
OV4 xenografts (p <0.01).Tumor volumes were measured twice weekly.
Error bars represent the standard error of the mean.
FIGURE 5 | MRK-003 and paclitaxel synergize to inhibit growth of
platinum-resistant ovarian tumors.Three independent cohorts of mice
bearing xenografts derived from clinically platinum-resistant serous ovarian
cancer were randomly divided into four groups. Each group received
vehicle, paclitaxel alone, MRK-003 alone or paclitaxelCMRK-003.
Signiﬁcantly heightened inhibition of tumor growth was observed upon
combination treatment with paclitaxelCMRK-003, compared with
treatment with either drug alone (p <0.03).Tumors were measured twice
weekly. Error bars represent the standard error of the mean. OV5 (A); OV6
(B); and OV7 (C).
formation (26). Others found that down regulation of g-secretase
activity reduced Notch1 and Hes1 mRNA and protein in the same
A2780 OvCa cells and this decrease correlated with a decrease in
cell proliferation (36). Since pan inhibition of g-secretase likely
inhibits activation of all Notch receptors,the observed effects may
not be due to speciﬁc disruption of Notch1 signaling. Rose and
colleagues (22) provided more direct evidence of Notch1 involve-
mentincellproliferationbysiRNA-mediatedreductionof Notch1
levels. The decrease in Notch1 in response to siRNA correlated
with decreased cell proliferation. Thus, the in vitro data suggest
that Notch1 signaling can inﬂuence the biology of OvCa.
Notch3 has also been implicated in the pathology of OvCa as
its expression is evident in a signiﬁcant number of analyzed OvCa
samples. Unlike Notch1, however, investigators have focused on
nuclear localization of Notch3 as a functional marker of pathway
activation(25,27,29,47).LikeNotch1,Notch3wasalsoexpressed
at much lower levels in benign ovarian tissue when compared to
malignantsamples(25,29),andhigherexpressionlevelswereasso-
ciatedwitheitheradvancedstage(29)orrecurrentdisease(28,48).
At the genomic level,the Notch3 gene was ampliﬁed in a cohort of
OvCa samples, as detected by ﬂuorescence in situ hybridization,
and this ampliﬁcation positively correlated with increased Notch3
proteinexpression(24).Thisﬁndingwassupportedbyrecentdata
from TCGA, which also showed that Notch3 was ampliﬁed in
serous ovarian carcinoma (2). Our data support the ﬁnding that
cleavedNotch3ispresentinprimaryOvCasamplesandlikelycon-
tributestothepathologyofOvCa(24,25,39,48).BlockingNotch3
signalingbyaGSIoraNotch3speciﬁcsiRNAreducedcellnumber
and led to an increase in apoptosis in OVCAR3 and A2780 OvCa
lines(24).Interestingly,theNotchligandJagged-1wasabundantly
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expressed in both OvCa cell lines and benign mesothelial cells
derived from tumors (25). Both gene knockdown of Jagged-1 and
transfection of the Notch3 intracellular domain (NICD3) suggest
the existence of a juxtacrine loop that impacts ovarian cell-cell
adhesion and tumor growth (25).
While Notch3 appears to play a role in OvCa cell prolifer-
ation, tumor growth, and metastasis, additional investigations
have implicated Notch signaling in chemoresistance (28, 39,
48). Knockdown of Notch3 sensitizes OvCar3 cells to carbo-
platin (28). Additionally, Notch3 is overexpressed in cisplatin and
cisplatin/paclitaxel-resistant OvCa cell lines and its inactivation
by GSI or siRNA reverses this resistance (48). More recently,
OVCA429 cells that were transduced with a retroviral vector
expressing NICD3 showed an increase in expression of smooth
muscle actin, Slug and Snail, consistent with an epithelial to
mesenchymal transition. Interestingly, this shift was associated
with an increase in resistance to carboplatin-induced apoptosis
(49). McAuliffe and colleagues (39) suggested that tumorigenic
OvCa stem cell (CSC) populations deﬁned as CD44C cells or
the side population fraction [reviewed by Foster et al. (50)]
were decreased with inhibition of g-secretase activity. These
data suggest that Notch signaling may support populations of
CSCs in OvCa that are resistant to conventional cytotoxic ther-
apies. Notch signaling can modulate other signaling pathways
that may inﬂuence CSC function. Speciﬁcally, the Notch target
Hes1 modulates Gli1 expression and Hedgehog signaling pro-
viding another mechanism of therapeutic resistance (51). Inhi-
bition of Hedgehog signaling has been shown to augment the
effect of P/C as well as delay recurrence of disease in a PDX
model of OvCa (44). Given that Notch signaling may support
CSC activity in OvCa, inhibition of the Notch pathway could
selectively target tumor-initiating populations and act to restore
chemosensitivity. This leads to the hypothesis that Notch pathway
inhibition in OvCa would produce the most robust effects in a
platinum-resistant tumor.
Our investigation suggests a GSI in combination with con-
ventional cytotoxic chemotherapy signiﬁcantly improves the anti-
tumor effects in primary human OvCa xenografts known to be
clinically resistant to platinum therapy. This extends the previous
ﬁndings by McAuliffe and colleagues who demonstrated the efﬁ-
cacy of targeting the Notch pathway in xenografts derived from
established OvCa cell lines (39). While this elegant study demon-
stratedGSIinducedanti-tumoractivityrestoredchemosensitivity,
it was unclear if primary-derived ovarian tumors would respond
to therapy in vivo in the same fashion. From a clinical perspec-
tive, platinum sensitivity, deﬁned as a >6month progression-free
interval after platinum-based therapy, is one of the most impor-
tant prognostic factors for women with OvCa (52, 53). In order
to better understand the in vivo response to GSI, we utilized
PDXs derived from women with known platinum-sensitive or
platinum-resistant disease. We observed that single agent MRK-
003signiﬁcantlyinhibitedtumorgrowthoftwoofthreeplatinum-
sensitive ovarian tumors, as well as one out of three platinum-
resistanttumors.WhenwecombinedGSIwithconventionalcyto-
toxic therapy, synergistic activity occurred only in the clinically
deﬁned platinum-resistant tumors. These ﬁndings support data
showing that inhibition of Notch signaling increases sensitivity
to chemotherapy (32, 39), implying that the Notch pathway is
involved in the development of chemoresistance.
Currently,earlyphaseclinicaltrialsassessingtreatmentefﬁcacy
of either single agent GSI or monoclonal antibodies focused on
disruption of ligand binding have been conducted in a number of
solid tumors including thyroid, non-small cell lung, desmoids,
and OvCas (54). The overall promising efﬁcacy of disrupting
Notch signaling has been tempered by some adverse events,which
are primarily gastrointestinal (55, 56). In our study, we used the
pan GSI MRK-003 whose clinical analog MK-0752 is in develop-
ment for treatment of several solid malignancies (56). Although
treatment with other GSIs has resulted in toxicity, we did not
observeanyexcessiveweightlossortreatmentrelateddeathinour
experiments.
ThesuccessoftargetedtherapiesinhibitingNotchsignalingwill
alsodependuponthedevelopmentofbiomarkersthatcanidentify
thosepatientswhoaremostlikelytorespond(54).Currently,there
is no universal biomarker that indicates Notch family dependence
and is correlated with response to a particular GSI. This objective
may become more complicated given recent evidence that Notch
signaling can serve an oncogenic or tumor suppressor function
dependingonthediseasecontext(57).Weobservednocorrelation
between baseline Notch1 or Notch3 protein levels and response
to treatment with MRK-003 alone in any of the ovarian tumors
we analyzed. A marked decrease in Hes1 mRNA expression was
observed in both the platinum-sensitive and platinum-resistant
PDXs following GSI therapy (data not shown), conﬁrming that
this downstream marker of on target effect is also of limited value
for associating anti-tumor effect. Recent work examining the efﬁ-
cacyof MRK-003inpancreaticcancerxenograftssimilarlydidnot
identify a clear biomarker (9).
In conclusion, this pilot investigation suggests speciﬁc Notch
family members are variably expressed in OvCa and that MRK-
003-mediated inhibition of Notch signaling reduces OvCa cell
proliferation in vitro and inhibits tumor growth in vivo. While
single agent anti-tumor activity was observed in many of the PDX
analyses,GSIimprovedconventionalcytotoxictherapyexclusively
incombinationwithpaclitaxelinthoseOvCatumorsknowntobe
clinically platinum-resistant. Our results support the rationale for
further investigation of the pre-clinical and clinical effectiveness
of GSIs in OvCa, especially in the platinum-resistant setting.
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